comparemela.com

Latest Breaking News On - Iaso bio - Page 1 : comparemela.com

IASO Bio Announces U S FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

/PRNewswire/ IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative.

Wei wangUnited statesEquecabtagene autoleucelJinhua zhangLancet regional healthDrug administrationChina national medical products administrationInvestigational new drugRelease syndromeCell associated neurotoxicity syndromeMyasthenia gravis activitiesDaily living scoreQuantitative myasthenia gravis scoreMyasthenia gravis qualityLife scoreModified rankin score

Iaso Bio Cleared to Start US Clinical Trials of CAR T-Cell Therapy in Myasthenia Gravis

Iaso Bio Cleared to Start US Clinical Trials of CAR T-Cell Therapy in Myasthenia Gravis
precisionmedicineonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from precisionmedicineonline.com Daily Mail and Mail on Sunday newspapers.

Jinhua zhangIaso bioDrug administrationMyasthenia gravis activitiesDaily living scoreMyasthenia gravis qualityBio founder

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

/PRNewswire/ IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell.

United statesEquecabtagene autoleucelUmoja biopharmaAlan fuDavid fontanaUmoja vivovecUmoja biopharma incChina national medical products administrationGreater chinaChief financial officerChief operatingChief business officerNew drug applicationNational medical products administrationMedia contactIaso bio

IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody.

Lugui qiuAdimab incyteChunrui liEli lillyA equecabtagene autoleucelEquecabtagene autoleucelInnovent biologicsInnovent biologics incInternational myeloma societyHuazhong university of science technologyChinese academy of medical science hematology hospitalMd anderson cancer centerTongji medical collegeChina national medical products administrationComplete responseAbstract code

China s NMPA Approves Iaso Bio, Innovent Biologics Fucaso in Multiple Myeloma

Chinese regulators approved the first autologous BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma patients.

Iaso bioDrug administrationChina national medical products administrationNational medical products administrationInnovent biologic

vimarsana © 2020. All Rights Reserved.